title: Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro.
abstract: OBJECTIVE
  To evaluate the antitumor reactivity of splenocytes primed in vivo with dendritic cell (DC) based vaccine and secondarily activated with cocktail of cytokines in vitro.
  
  
  METHODS
  Tumor lysate pulsed DC were used to generate effector T cells in the murine L615 leukemia model. DC were induced and pulsed with tumor lysate. The splenocytes from the DC based vaccine primed mice were termed VPS. Some VPS were activated with anti-CD3 alone (VPS-CD3), the other cells were activated with a cocktail of cytokines including IFN-gamma, IL-1beta, anti-CD3 and IL-2 (VPSC).
  
  
  RESULTS
  Both VPS and VPS-CD3 showed moderate IFN-gamma release to stimulatory tomor cells in vitro and antitumor capacity in vivo. However, VPSC showed much higher IFN-gamma release and far superior antitumor capacity than the other cells in this leukemia model.
  
  
  CONCLUSIONS
  The result here indicates that tumor lysate pulsed DC can be used as a strategy to generate effector T cells which can be further activated with a cocktail of cytokines for adoptive immunotherapy.
authors.affiliation: Department of Medical Oncology, Medical School Hospital of Qingdao University, Qingdao 266003, China. wozhangsheng@263.net.
authors.forename: Sheng
authors.initials: S
authors.lastname: Zhang
authors.forename: Wen-Feng
authors.initials: WF
authors.lastname: Li
authors.forename: Hong-Jun
authors.initials: HJ
authors.lastname: Zhang
authors.forename: Qin
authors.initials: Q
authors.lastname: Wang
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured / Q000276:immunology / Q000637:transplantation; D016207:Cytokines / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D003713:Dendritic Cells / Q000276:immunology* / Q000637:transplantation; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D007371:Interferon-gamma / Q000378:metabolism / Q000494:pharmacology; D007375:Interleukin-1 / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007942:Leukemia, Experimental / Q000276:immunology* / Q000628:therapy; D051379:Mice; D008815:Mice, Inbred Strains; D016853:Muromonab-CD3 / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000276:immunology*; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000528:radiation effects
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines; D007375:Interleukin-1; D007376:Interleukin-2; D016853:Muromonab-CD3; D007371:Interferon-gamma